GNFT - GENFIT

-

$undefined

N/A

(N/A)

GENFIT NasdaqGS:GNFT Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Location: Parc Eurasanté, Loos, 59120, France | Website: https://www.genfit.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

189M

Cash

81.79M

Avg Qtr Burn

N/A

Short % of Float

0.15%

Insider Ownership

0.00%

Institutional Own.

0.52%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Iqirvo® (elafibranor) Details
Primary biliary cholangitis, Liver disease

Approved

Quarterly sales

VS-01 Details
Acute-on-Chronic liver failure, Liver disease

Phase 2

Data readout

Nitazoxanide (NTZ) Details
Non-alcoholic steatohepatitis , Acute-on-Chronic liver failure, Liver disease

Phase 2

Initiation

GNS561 Details
Liver disease, Cholangiocarcinoma

Phase 1b

Data readout

Iqirvo® (elafibranor) Details
Non-alcoholic steatohepatitis

Failed

Discontinued